Health ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Drug Efficacy Cancer Treatments Alzheimer's Disease Gene Therapy Cancer Treatment Obesity Treatment Obesity Treatments Major Depressive Disorder Phase 3 Trials Drug Safety Weight Loss Treatments Atopic Dermatitis Hypertension Multiple Myeloma Monoclonal Antibodies Phase 3 Studies Efficacy Studies Weight Loss Medications Breast Cancer Regulatory Affairs Autoimmune Diseases Stroke Prevention Tirzepatide Semaglutide Phase 2 Trials Patient Safety Experimental Drugs Eli Lilly Duchenne Muscular Dystrophy Study Results Investigational Drugs Pulmonary Sarcoidosis Cardiovascular Health HIV Treatment Mental Health Multiple Sclerosis Pain Management Type 2 Diabetes Epilepsy Treatment Guidelines Nebulized Tyvaso Biopharmaceuticals C3 Glomerulopathy (C3G) Product Development Benefit-Risk Assessment Cardiovascular Risk Epilepsy Treatments Lecanemab Olezarsen EMBER-3 Study VTX3232 EMBER-3 Neurological Disorders Lung Cancer Treatments Weight Loss Eczema Narcolepsy Treatment Phase III Trials Drug Approval Lung Cancer Cochrane Reviews Alcohol Use Disorder COPD Late-stage Studies Garetosmab Cannabis Medications Ulcerative Colitis PCSK9 Inhibitors DYNE-251 Chronic Myeloid Leukemia Giredestrant Obefazimod IgA Nephropathy Vaccine Efficacy Risk-Based Oversight Systems NG101 GLP-1 Receptor Agonists Chronic Lymphocytic Leukemia Gaucher Disease FDA Approval Geographic Atrophy Side Effects Dementia Treatments Phase Ib Studies Anticoagulants Epilepsy Treatment Weight Management Ziihera Alzheimer's Treatment Novo Nordisk Diabetes Medications Pediatric Medicine COVID-19 Treatments Selective Estrogen Receptor Modulators Nuzolvence and Blujepa Wegovy Patient Outcomes Medication Efficacy

Soleno Faces Securities Class Action Over Disclosures on Prader-Willi Drug VYKAT XR

Investors are being urged to seek lead-plaintiff status by May 5 following allegations that Soleno downplayed DCCR safety risks.

India Poised for Semaglutide Generics as Patent Expires, Prices Expected to Plunge

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Mereo BioPharma Investors Face April 6 Deadline in Lawsuits Over Failed Setrusumab Trials

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

NEJM Publishes Phase 3 Data Showing Ajovy Reduces Pediatric Migraine Days

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial